In the single-center, Phase I trial, 30 people with metastatic kidney cancer were randomized to receive cabozantinib, an inhibitor of vascular endothelial growth factor receptor, and targeted ...

Following approval by the European Commission, Cabometyx (cabozantinib ... advanced renal cell carcinoma, although it initially failed to produce convincing results in prostate cancer.

Cabometyx is also approved for advanced kidney cancer, liver cancer and differentiated ... The recommended Cabozantinib (Cabometyx) dose is 60 mg once daily for patients 12 and older weighing ...

leading to cancer cell death. Clear cell RCC (ccRCC) is almost universally associated with HIF-2a dysregulation. Casdatifan is currently being evaluated in ARC-20, a Phase 1/1b study in renal cell ...

Cabometyx (cabozantinib) has been recommended for ... Rose Woodward, co-founder of patient organisation Action Kidney Cancer, said the approval is “welcome news for the kidney cancer community, ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.